MX391017B - Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. - Google Patents

Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.

Info

Publication number
MX391017B
MX391017B MX2017002852A MX2017002852A MX391017B MX 391017 B MX391017 B MX 391017B MX 2017002852 A MX2017002852 A MX 2017002852A MX 2017002852 A MX2017002852 A MX 2017002852A MX 391017 B MX391017 B MX 391017B
Authority
MX
Mexico
Prior art keywords
conditions
lymphocytes
infiltrate
activation
mils
Prior art date
Application number
MX2017002852A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002852A (es
Inventor
Ivan M Borrello
Kimberly A Noonan
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2017002852A publication Critical patent/MX2017002852A/es
Publication of MX391017B publication Critical patent/MX391017B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2017002852A 2014-09-04 2015-09-04 Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas. MX391017B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462045782P 2014-09-04 2014-09-04
US201562186040P 2015-06-29 2015-06-29
PCT/US2015/048536 WO2016037054A1 (en) 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Publications (2)

Publication Number Publication Date
MX2017002852A MX2017002852A (es) 2017-05-30
MX391017B true MX391017B (es) 2025-03-21

Family

ID=55440392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002852A MX391017B (es) 2014-09-04 2015-09-04 Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.

Country Status (13)

Country Link
US (7) US9687510B2 (https=)
EP (2) EP3922254A1 (https=)
JP (2) JP6865160B2 (https=)
KR (1) KR20170067751A (https=)
CN (1) CN107109364A (https=)
AU (2) AU2015311761B2 (https=)
CA (1) CA2959994C (https=)
DK (1) DK3188740T3 (https=)
ES (1) ES2877108T3 (https=)
IL (2) IL250746B (https=)
MX (1) MX391017B (https=)
PT (1) PT3188740T (https=)
WO (1) WO2016037054A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US9687510B2 (en) * 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CA2991040A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric receptors therapy
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
EP3735256A4 (en) 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
WO2020198031A1 (en) * 2019-03-22 2020-10-01 Windmil Therapeutics Inc. Lung cancer specific marrow infiltrating lymphocytes and uses thereof
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
WO2025160242A1 (en) * 2024-01-23 2025-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of generating tils from cerebro spinal fluid for leptomeningeal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3243600A (en) 1999-02-23 2000-09-14 Kathleen S. Carswell Improved method of culturing t cells
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
WO2008147482A2 (en) * 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
BR112014007947A2 (pt) 2011-10-03 2017-04-18 Univ Los Andes método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
JP2014090678A (ja) * 2012-11-01 2014-05-19 Ito En Ltd 容器詰野菜汁及び／又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び／又は果汁含有飲料の呈味劣化防止方法
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2020512284A (ja) * 2016-12-22 2020-04-23 ウィンドミル セラピューティクス インコーポレイテッド 免疫系調節組成物および方法
EP3735256A4 (en) * 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Also Published As

Publication number Publication date
IL250746A0 (en) 2017-04-30
PT3188740T (pt) 2021-06-23
AU2015311761A1 (en) 2017-04-06
KR20170067751A (ko) 2017-06-16
WO2016037054A1 (en) 2016-03-10
IL276347B (en) 2021-10-31
US10406178B2 (en) 2019-09-10
EP3188740A4 (en) 2018-05-16
JP2017527286A (ja) 2017-09-21
MX2017002852A (es) 2017-05-30
US11406666B2 (en) 2022-08-09
US20230000919A1 (en) 2023-01-05
US9687510B2 (en) 2017-06-27
JP7197213B2 (ja) 2022-12-27
AU2021200648A1 (en) 2021-03-04
US20170266232A1 (en) 2017-09-21
JP2021104048A (ja) 2021-07-26
US20170258838A1 (en) 2017-09-14
EP3188740B1 (en) 2021-04-14
ES2877108T3 (es) 2021-11-16
US20160331781A1 (en) 2016-11-17
AU2015311761B2 (en) 2020-11-12
US11160830B2 (en) 2021-11-02
CA2959994A1 (en) 2016-03-10
US20220016172A1 (en) 2022-01-20
US20190298768A1 (en) 2019-10-03
JP6865160B2 (ja) 2021-04-28
US10172887B2 (en) 2019-01-08
EP3922254A1 (en) 2021-12-15
EP3188740A1 (en) 2017-07-12
DK3188740T3 (da) 2021-06-07
US20190350982A1 (en) 2019-11-21
CN107109364A (zh) 2017-08-29
IL276347A (en) 2020-09-30
IL250746B (en) 2020-08-31
CA2959994C (en) 2023-04-11

Similar Documents

Publication Publication Date Title
MX391017B (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
JOP20200016B1 (ar) أجسام مضادة لـ cd137
PH12017501748B1 (en) Antibodies to icos
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2020006668A (es) Anticuerpos para lilrb2.
MY199019A (en) Pd-1 antibodies
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
MY195110A (en) Antibodies to PD-1 and uses Thereof
BR112017020952A2 (pt) método de tratamento de câncer, composição e uso da composição
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MX2021002900A (es) Composicion con complejos de nanoparticulas/anticuerpos de paclitaxel unidos a albumina para usarse al tratar linfoma.
MX2016016617A (es) Tratamiento de mielomas.
MX2020010375A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX381278B (es) Composición para la estimulación ovárica controlada.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
BR112016012248A2 (pt) método de tratamento de nefropatia
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX2016010229A (es) Conjugados del factor vii.
PH12017501897A1 (en) 2-thiopyrimidinones
GB201105129D0 (en) Compositions and methods for treating, diagnosing and monitoring disease